TWiV reviews an experimental, intranasally administered SARS-CoV-2 vaccine that utilizes adenovirus vectors to deliver three viral proteins and induces immunity to ancestral and variant isolates.
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler
Click arrow to play
Download TWiV 867 (128 MB .mp3, 107 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Dorothy Horstmann (Wikipedia) 9:23
- Intranasal SARS-CoV-2 experimental vaccine (Cell) 14:18
- t-SNE (Wikipedia) 43:52
- Timestamps by Jolene. Thanks!
Weekly Picks 1:29:40
Kathy – 477-mile-long megaflash lightning in Seattle Times (originally Washington Post) and extra info from Rich World Meteorological Org
Rich – NIAID Global Research (Mali)
Alan – New method for recycling electric car batteries
Vincent – Q&A with A&V
Listener Picks
Addie – Vaccine Podcast
Jennie – Dr. Katelyn Jetelina, aka Your Local Epidemiologist
Intro music is by Ronald Jenkees
Send your virology questions and comments to twiv@microbe.tv
The experimental mice in the paper discussed in this episode almost certainly would’ve had prior exposure to human adenovirus via their caretakers. They would be very unlikely to have had prior exposure to chimpanzee adenovirus virus. I’m wondering how this would have affected the results in the paper.